Scientists Edited Genes in a Living Person and Saved His Life
Key topics
Diving into the world of gene editing, a groundbreaking study has successfully used CRISPR to treat a rare genetic disorder in a living patient, sparking a lively discussion around the scientific breakthrough and its regulatory implications. Commenters are abuzz about what made this treatment possible now, with some pointing to the relatively recent development of CRISPR-Cas9 in 2012 and others highlighting the complex history leading up to this achievement. As one commenter astutely observed, the 13-year translation timeline from CRISPR's invention to this in vivo application is "unusually fast," while others are curious about the regulatory approvals that paved the way. The conversation is filled with insightful perspectives on the science, history, and future of gene editing.
Snapshot generated from the HN discussion
Discussion Activity
Active discussionFirst comment
57m
Peak period
16
2-4h
Avg / period
4.4
Based on 44 loaded comments
Key moments
- 01Story posted
Dec 27, 2025 at 1:26 PM EST
6d ago
Step 01 - 02First comment
Dec 27, 2025 at 2:23 PM EST
57m after posting
Step 02 - 03Peak activity
16 comments in 2-4h
Hottest window of the conversation
Step 03 - 04Latest activity
Dec 28, 2025 at 9:51 PM EST
4d ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.
https://www.nejm.org/doi/full/10.1056/NEJMoa2504747
With CRISPR, it took a long time to figure out how to reliably edit just the gene you want and acceptably minimize off-target edits, including by delivering the therapeutic to just the organ affected and getting the dose and release right.
The public is understandably leery about experimental medical techniques. If they had killed this newborn child with CRISPR therapy, then it might have set created a backlash delaying translation of this technique for years, possibly decades.
In biomedicine, we’re always looking for therapies that approximate the level of precision control available in software. Unfortunately, it’s never more than an approximation, and our ability to measure and predict the size of that error is always limited. That is why the field moves slowly.
Also do we know that this was CRISPR?
It lasted for around a year and a half (https://www.youtube.com/watch?v=aoczYXJeMY4) before the effect mostly wore off. He took it orally, so it only affected his intestinal lining, and I presume it didn't effect enough stem cells to get a permanent effect, but it would still be usable as something taken annually, which is still far less often than any medication.
I'm using Chrome on Android
"In a race against time, scientists and doctors across the U.S. developed the first in vivo gene therapy, thanks to decades of medical research."
Look at how the Nixon administration and congress gutted NASA. It took nearly 40 years to crawl out of the hole in the roadmaps that their shortsighted stupidity created. We could have had reusable rockets, aerospike engines and Nuclear Thermal Propulsion in the early 1980s. Instead we got halfway measures like the space shuttle and the ISS that both ate budget but didn't create the required innovation for lower cost to orbit.
Better start learning mandarin.
After the US canceled the SSC, Europe built the LHC. The LHC isn't a one for one replacement of the SSC, but it would probably not have been built if the SSC had been built. What scientific projects would Europe have built instead? What did we lose?
But only to the extent that the regime fails to get its way.
If the regime continues, they will definitely push us back to a dark age, partially intentionally, partially through not caring about the future or being too stupid to figure out the consequences. And Theil, Musk, Vance and that whole lot are part of the crew pushing for that — technology for me but not for thee.
https://www.youtube.com/watch?v=GgqwdYAmoFQ
It depends on the specific disorder that’s being treated. For some of them, targeting a fraction of the affected cells is enough to get the desired effect.
Is this approval process public? I'm just curious where the current boundaries lie.
Discussion then: https://news.ycombinator.com/item?id=43997636
https://pmc.ncbi.nlm.nih.gov/articles/PMC12713542/
Why not?
Because by the second day of incubation, any cells that have undergone reversion mutation give rise to revertant colonies, like rats leaving a sinking ship; then the ship... sinks.
What about EMS-3 recombination?
We've already tried it - ethyl, methane, sulfinate as an alkylating agent and potent mutagen; it created a virus so lethal the subject was dead before it even left the table.
Then a repressor protein, that would block the operating cells.
Wouldn't obstruct replication; but it does give rise to an error in replication, so that the newly formed DNA strand carries with it a mutation - and you've got a virus again... but this, all of this is academic.
You were made as well as we could make you.
(without paywall)